173 related articles for article (PubMed ID: 15585480)
41. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
43. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
44. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
45. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI.
Ruf J; Lopez Hänninen E; Oettle H; Plotkin M; Pelzer U; Stroszczynski C; Felix R; Amthauer H
Pancreatology; 2005; 5(2-3):266-72. PubMed ID: 15855825
[TBL] [Abstract][Full Text] [Related]
46. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
47. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
[TBL] [Abstract][Full Text] [Related]
48. FDG PET/CT in the detection of recurrent rectal cancer.
Kau T; Reinprecht P; Eicher W; Lind P; Starlinger M; Hausegger KA
Int Surg; 2009; 94(4):315-24. PubMed ID: 20302028
[TBL] [Abstract][Full Text] [Related]
49. Information feedback of
Mu Y; Gui J; Lang Z; Ren C; Yan L; Liu H; Liang J; Feng H
J Infect Public Health; 2020 Sep; 13(9):1336-1341. PubMed ID: 31289004
[TBL] [Abstract][Full Text] [Related]
50. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
[TBL] [Abstract][Full Text] [Related]
51. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
52. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.
Nahas Z; Goldenberg D; Fakhry C; Ewertz M; Zeiger M; Ladenson PW; Wahl R; Tufano RP
Laryngoscope; 2005 Feb; 115(2):237-43. PubMed ID: 15689742
[TBL] [Abstract][Full Text] [Related]
53. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
55. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities.
Filippi V; Malamitsi J; Vlachou F; Laspas F; Georgiou E; Prassopoulos V; Andreou J
Nucl Med Commun; 2011 Feb; 32(2):85-90. PubMed ID: 21127445
[TBL] [Abstract][Full Text] [Related]
56. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis.
Rabkin Z; Israel O; Keidar Z
J Nucl Med; 2010 Jul; 51(7):1015-20. PubMed ID: 20554733
[TBL] [Abstract][Full Text] [Related]
57. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
Fuster D; Chiang S; Johnson G; Schuchter LM; Zhuang H; Alavi A
J Nucl Med; 2004 Aug; 45(8):1323-7. PubMed ID: 15299056
[TBL] [Abstract][Full Text] [Related]
58. FDG PET and PET/CT for colorectal cancer.
Delbeke D; Martin WH
Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
[TBL] [Abstract][Full Text] [Related]
59. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management.
Champion L; Brain E; Giraudet AL; Le Stanc E; Wartski M; Edeline V; Madar O; Bellet D; Pecking A; Alberini JL
Cancer; 2011 Apr; 117(8):1621-9. PubMed ID: 21472709
[TBL] [Abstract][Full Text] [Related]
60. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
